Fifth Third Bancorp Intellia Therapeutics, Inc. Transaction History

Fifth Third Bancorp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$23.82 - $32.8 $190 - $262	-8 Reduced 5.06%	150 $4,000
Q4 2023 Jan 19, 2024	BUY	$23.16 - $32.34 $185 - $258	8 Added 5.33%	158 $4,000
Q1 2022 Apr 19, 2022	SELL	$58.27 - $118.99 $8,740 - $17,848	-150 Reduced 50.0%	150 $11,000
Q4 2021 Feb 01, 2022	BUY	$100.76 - $138.36 $28,112 - $38,602	279 Added 1328.57%	300 $35,000
Q3 2021 Oct 15, 2021	SELL	$132.37 - $176.78 $2,117 - $2,828	-16 Reduced 43.24%	21 $3,000
Q2 2021 Aug 06, 2021	BUY	$60.88 - $161.91 $2,252 - $5,990	37 New	37 $6,000
Q1 2019 May 14, 2019	SELL	$12.79 - $17.62 $25 - $35	-2 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $22 - $54	2 New	2 $0
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $4,253 - $5,379	-165 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $3,303 - $5,080	165 New	165 $5,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $707M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

Stay updated on Fifth Third Bancorp with notifications on news.